Objective-Recent data suggest that visit-to-visit variability of cholesterol is associated with cardiovascular events. We evaluated the role of lipid variability as a determinant of end-stage renal disease (ESRD). Approach and Results-Using nationally representative data from the Korean National Health Insurance System, 8 493 277 subjects who were free of ESRD and who underwent ≥3 health examinations during 2005 to 2010 were followed to the end of 2015. Total cholesterol (TC) variability was measured using the coefficient of variation, SD, and the variability independent of the mean. The primary outcome was the development of ESRD, defined as a combination of the relevant disease code and the initiation of renal replacement therapy. There were 11 247 cases of ESRD during a median followup of 6.1 years. There was a graded association between a higher TC variability and incident ESRD. In the multivariable adjusted model, the hazard ratios and 95% confidence intervals comparing the highest versus lowest quartiles of coefficient of variation of TC were 2.66 (95% confidence interval, 2.52-2.82). The results were consistent when the variability of TC was modeled using SD and variability independent of the mean and were independent of preexisting chronic kidney disease. Conclusions-Increasing TC variability was associated with an increasing incidence of ESRD. Visual Overview-An online visual overview is available for this article. 
C hronic kidney disease (CKD) is a growing public health problem. More than 10% of the adult population in the United States is estimated to have stage 1 to 4 CKD. 1 The estimated prevalence in Korea of CKD, including both reduced estimated glomerular filtration rate (eGFR) and albuminuria, is 8.2%, 2 and its prevalence is increasing worldwide with the growing prevalence of obesity and metabolic diseases. 3 CKD has substantial importance because it is considered a strong risk factor for cardiovascular morbidity and mortality.
Targeting modifiable factors has been frequently recommended as a first-line strategy for reducing the risks of kidney disease progression and cardiovascular disease (CVD) in patients with CKD. Previous studies have suggested that lipid abnormalities may contribute to the progression of kidney disease. [4] [5] [6] In a study of nondiabetic patients with primary chronic renal disease, elevated plasma concentrations of apolipoprotein B and low-density lipoprotein cholesterol, but not reduced concentrations of high-density lipoprotein cholesterol, were correlated with faster progression of renal insufficiency, even after controlling for proteinuria. 4 Previous meta-analyses of randomized trials have indicated that lowering low-density lipoprotein cholesterol might reduce the rate of loss of glomerular filtration by ≈1 mL/min per year. 5 An intensive treatment strategy with 80-mg atorvastatin reduced the risk of kidney failure by 31% compared with treatment with 10-mg atorvastatin. 6, 7 Recently, interest in the intraindividual variability of various physiological measures has led to the recognition of their role as a risk factor for health-related outcomes. For example, increased blood-pressure variability and lowered heart-rate variability have been repeatedly linked to adverse outcomes, such as vascular events, impaired cognition, and mortality. [8] [9] [10] [11] In addition, visit-to-visit variability in blood pressure (BP) has been shown to predict the risk of end-stage renal disease (ESRD), independent of the achieved systolic BP.
increased risk of cardiovascular events in subjects with coronary artery disease. [12] [13] [14] However, the role of lipid variability as a determinant of incident ESRD has not been evaluated. Moreover, previous studies on lipid variability have important limitations, such as being restricted to specific or high-risk populations, having a small sample size, or assessing only selected outcomes. [12] [13] [14] To understand better the association of lipid variability with adverse renal outcomes in the broader and general population, we analyzed nationally representative data from the Korean National Health Insurance System.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Baseline Characteristics of Study Population
The characteristics of participants classified by quartiles of coefficient of variation (CV) of TC are described in Table 1 . Subjects in higher quartiles of TC variability were older, more likely to be women, had a higher prevalence of comorbid conditions, and more frequently used lipid-lowering agents. Data are expressed as the mean±SD or n (%). P values for the trend were <0.0001 for all variables because of the large size of the study population. BP indicates blood pressure; CV, coefficient of variation; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; TC, total cholesterol; and VIM, variability independent of the mean.
Nonstandard Abbreviations and Acronyms
*Proteinuria was defined as having urinary protein ≥1+ on dipstick testing in fasting morning urine.
The mean TC levels in all 4 groups were ≈193 mg/dL. The CV values of TC in the Q1-Q4 groups were 3.88±1.35%, 7.30±0.85%, 10.56±1.10%, and 17.85±5.15%, respectively. Baseline levels of eGFR were comparable between groups. The proportion of subjects with proteinuria increased gradually from the subjects with the lowest to the highest TC variability. Similar patterns of baseline characteristics were noted by quartiles of SD and variability independent of the mean (VIM; Tables I and II in the online-only Data Supplement). P values for the trend were <0.0001 for all variables because of the large size of the study population. The baseline CV, SD, and VIM of TC were significantly higher in subjects with incident ESRD than in those without ESRD (Table 2) , although the baseline and mean TC levels did not differ greatly according to the occurrence of ESRD.
TC Variability and the Risk of ESRD
During a median (5%-95%) 6.1 (5.0-6.8) years of follow-up after the TC variability assessment period, 11 247 (0.13%; 0.22/1000 person-years) participants developed ESRD. The incidence of ESRD increased progressively with higher levels of TC variability in both subjects with baseline eGFR ≥60 and eGFR <60 mL/min per 1.73m 2 ( Figure 1 ; Figure II in the online-only Data Supplement). The incidence rate was ≈200% to 330% higher in the CV Q4 group compared with the other groups ( Table 3 ). An incrementally higher risk of ESRD was observed for higher CV quartiles compared with the lowest quartile group in all models. After adjusting for age, sex, body mass index (BMI), alcohol drinking, smoking, regular exercise, and income, the hazard ratios (HR) for incident ESRD were 1.15 (95% confidence interval, 1.08-1.23), 1.39 (95% confidence interval, 1.31-1.48), and 2.66 (95% confidence interval, 2.52-2.82) for the second, third, and fourth quartiles versus the first quartile of CV of TC, respectively ( Table 3 , model 4). TC variability as measured by SD or VIM was also an independent predictor of ESRD, even after full multivariable adjustment.
Risk of ESRD According to TC Variability and BMI Groups
The overall association between BMI and the risk of ESRD showed an inverted J curve ( Figure 2 ). Higher adjusted HRs of ESRD were observed in the highest TC variability (Q4) group, regardless of BMI category. When analyzed by multivariate Cox regression analysis, compared with normal BMI (18.5 ≤ BMI < 23.0) and the lowest 3 quartiles of TC variability, the subgroup with Q4 TC variability that was underweight had the highest risk of ESRD (HR, 2.49; 95% confidence interval, 2.11-2.92). The lowest risk was observed among individuals with class II obesity (30≤BMI<35) and TC variability Q1-Q3 (HR, 0.56; 95% confidence interval, 0.47-0.66). Results were consistent when the variability of TC was determined using SD and VIM ( Figure III in the online-only Data Supplement).
Subgroup Analyses
Analyses stratified by age, sex, the presence or absence of obesity, diabetes mellitus, hypertension, dyslipidemia, any malignancy, impaired renal function, CVD, and use of lipidlowering agents were performed (Figure 3) . The Q4 group of TC variability (Q4) remained predictive of ESRD in all studied subgroups compared with the Q1-Q3 groups. Higher adjusted HRs of incident ESRD were observed in the subgroup that was younger (< 55 years); male; not obese; without diabetes mellitus, dyslipidemia, or CVD; and not taking any lipidlowering agents. These findings were consistent when using other indices of variability, including SD and VIM (Figures IV and V in the online-only Data Supplement). To account for the possible influence of previous renal function on incident Data are expressed as the mean±SD or n (%). P values were <0.0001 for all variables because of the large size of the study population. BP indicates blood pressure; CV, coefficient of variation; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; TC, total cholesterol; and VIM, variability independent of the mean.
ESRD, we performed a subgroup analysis based on the presence of low GFR defined as baseline eGFR <60 mL/min per 1.73 m 2 . The associations between TC variability and ESRD were consistent in subjects with or without low GFR.
Sensitivity Analyses
When subjects with ESRD that occurred within 2 years of follow-up were excluded, the HRs were slightly attenuated, but the overall pattern of higher risk of developing ESRD at higher TC variability remained significant (Table 4 ). When the baseline TC level was used instead of the mean TC level in the Cox proportional hazards model 3, the results were nearly identical (Table III in the online-only Data Supplement). When the systolic BP and fasting blood glucose were used instead of hypertension and diabetes mellitus, we also found similar results (Table IV in the online-only Data Supplement). The number of TC measurements may influence the variability. To overcome this limitation, we performed sensitivity analyses with subjects who had 5 (Table V in the online-only Data Supplement) or 3 measurements of TC (Table VI in the online-only Data Supplement). An incrementally higher risk of ESRD was observed with higher variability quartile groups compared with the lowest quartile group in all models. Sensitivity analysis on subjects with 5 measurements of TC showed even higher HRs compared with the original analysis.
Discussion
In this nationwide population-based cohort study, we demonstrated that TC variability was associated with a higher A B C Figure 1 . Kaplan-Meier estimates of end-stage renal disease (ESRD)-free probability by quartiles of total cholesterol variability measured as coefficient of variation in the total population (A), baseline estimated glomerular filtration rate (eGFR) ≥60 (B), and baseline eGFR <60 population (C). risk for ESRD development during a 6.1-year follow-up period. A dose-response relationship was noted between higher TC variability and the primary outcome. The association persisted after multivariable adjustment for important potential confounders, including baseline eGFR, proteinuria, and underlying diseases. The results obtained using different indices of lipid variability were largely consistent. These data add to the evidence that TC variability is a risk factor for ESRD as well as for myocardial infarction, stroke, and all-cause mortality. [12] [13] [14] Our study also demonstrated a greater impact of lipid variability in underweight subjects relative to that in normal-weight subjects.
A significant relationship was observed between TC variability and progression to ESRD. This is relevant because the glomerulus is adversely affected by the same pathophysiological factors that lead to atherosclerosis, including dyslipidemia, hypertension, endothelial dysfunction, insulin resistance, inflammation, and oxidative stress. 15 Glomerular lipid deposits and the appearance of foam cells accompany renal injury in models of hyperlipidemia. 15, 16 High fluctuations in blood cholesterol could directly contribute to the progression of ESRD by leading to instability of the vascular wall owing to fluctuations in the composition of lipid deposits.
Even though the prospective association between TC variability and incidence of ESRD was significant and independent of other risk factors, the potential for reverse causality is of concern. It is possible that lipid variability accelerates renal disease progression or that renal disease increases lipid variability. Two of the significant factors that determine the levels of plasma cholesterol-rich lipoproteins are deterioration in renal function and the degree of proteinuria. 17 Patients with impaired renal function exhibit increased concentrations of triglycerides, even when their serum creatinine levels are within normal limits. Patients with nephrotic-range proteinuria exhibit an acquired lowdensity lipoprotein-receptor deficiency. 17 People with more significant renal disease might have greater TC variability because of changes in their lipid metabolism. In our study, subjects in the higher TC variability group (Q4) were more likely to have albuminuria than those with lower TC variability (Q1-Q3). However, after controlling for baseline GFR and proteinuria as confounders, we found a consistent association between TC variability and incident ESRD. Moreover, a sensitivity analysis that excluded subjects with outcomes occurring in the first 2 years of follow-up revealed similar results.
The rate of progression to ESRD in the underweight group (BMI <18.5 kg/m 2 ) with high TC variability (Q4) was higher than in the remaining groups. Underweight was previously associated with an increased risk of progression of impaired renal function. 18 Additional protein wasting caused by chronic disease progression might be less well tolerated in the underweight group because of their low protein reserves. In an Australian population with stage 3 to 4 CKD, 19 a BMI in the overweight (25-29.9 kg/m 2 ) or obesity class I/II (30-39.9 kg/ m 2 ) range was associated with a reduced risk of progression of renal disease and mortality, although the results were no longer significant when the BMI exceeded 40 kg/m 2 . Although BMI cutoff values for obesity differ according to the ethnic group, 20, 21 subjects with a BMI of 25 to 34.9 kg/m 2 tend to have the lowest risk of progression of ESRD, regardless of ethnicity. A slightly elevated BMI potentially represents better overall nutrition, a high muscle mass, and an increased ability to adapt to the protein-energy wasting state commonly observed in kidney disease. 18 Therefore, lipid variability may render subjects more susceptible to a poor outcome when their BMI is low. In contrast, excessive BMI has also been reported as a risk factor for the incidence of ESRD in several studies of CKD, [22] [23] [24] and focal segmental glomerulosclerosis and glomerulomegaly are often observed in obese people. Excess adiposity may be associated with ectopic lipid accumulation in the kidney, which in turn may be associated with structural and functional changes that mediate obesity-related renal disease. 22 The REGARDS study (reasons for geographic and racial differences in stroke) data showed that metabolic health modified the association of BMI with the risk of incident ESRD, in that a higher BMI was associated with lower ESRD risk in those without, but not in those with, metabolic syndrome. 23 It is also possible that the improved nutritional status, elevated adiponectin levels, and increased energy reserves associated with an elevated BMI may not only negate but also dominate the deleterious proinflammatory and atherogenic effects of the increased fat mass. 23, 24 High sympathetic and low parasympathetic tone is associated with CVD. Low heart-rate variability-a marker for sympathetic activation-is related to the progression of renal dysfunction. 25 Low heart-rate variability may directly contribute to adverse renal outcomes by increasing atherosclerosis, vasoconstriction, arrhythmia, sodium retention, renin release, and BP. Increased systolic BP variability has also been linked to adverse renal outcomes. 26 Increased BP variability causes greater stress on blood vessels and leads to endothelial dysfunction, thereby promoting early targetorgan damage. 27 Although the mechanisms are different, these fluctuations in physiological measures, such as BP, heart rate, glucose, and lipid levels could cause adverse health outcomes or be predictors of worse outcomes. Patients with higher variability in both low-density lipoprotein cholesterol and BP had higher incidence of cardiovascular events compared with lower variability in both parameters, 28 suggesting an additive effect of different variability parameters on the risk of CVD. Increased variabilities in multiple parameters could be caused by variable compliance to healthy diet or drug treatment. However, in a previous study, the correlation between cholesterol variability and BP variability was poor. 28 In our study, the correlations between TC variability and systolic BP variability (r=0.058) or glucose variability (r=0.107) were also not strong.
There are limitations to our study. First, this was an observational study, and, therefore, the association found between TC variability and renal end-points may not be causal. As mentioned above, reverse causality is plausible because people with more significant renal disease (or proteinuria) might have greater TC variability. However, to minimize the possible effects of reverse causality, subjects with preexisting ESRD were excluded. A sensitivity analysis that also excluded subjects with ESRD occurring in the first 2 years of follow-up also showed similar results. Moreover, we found that the associations between TC variability and ESRD were consistent in subjects with and without low GFR. Second, the causes of renal disease were not identifiable in our study. Third, we defined proteinuria by dipstick testing and, therefore, did not quantify the proteinuria. However, measuring proteinuria by dipstick testing was useful in identifying the development of ESRD. 29 Fourth, the study population consisted of Korean men and women; therefore, it is uncertain whether these findings can be generalized to other ethnic groups. Lastly, there is no consensus on the ideal statistical measure of visit-to-visit TC variability. The degree of TC variability is in general roughly proportional to mean TC levels, and this dependence of TC variability on mean TC has led to the use of methods that assess TC variability in normalized units and are aimed at accounting for the mean TC level. This can be done by computing CV or VIM. In our study, the results were similar and consistent across all indices of TC variability.
The current study has several distinguishing points. To our knowledge, it is the first study of the relationship between TC variability and ESRD development in a large general population, using a well-established and validated longitudinal national database for 6 years. Adiposity is an important risk factor for ESRD and may be partially responsible for the association between lipid variability and ESRD. However, we found a more significant association in underweight subjects: underweight subjects with high TC variability had the highest risk of ESRD. Our study demonstrated a greater impact of lipid variability on low-risk groups, such as younger age, subjects without diabetes mellitus, dyslipidemia or CVD, and not on lipid-lowering agents. We could assume that not the medication or underlying diseases but the fluctuation of TC level per se could have affected the outcome. Although the precise mechanism is unclear, a more uniform and less variable lipid levels might be important for preventing progression to ESRD, especially in the low-risk subjects. Future studies should examine whether reducing the variability in lipid parameters decreases the risk of progression to ESRD.
